9 completed, 2 terminated, 1 unknown, 1 withdrawn. 9 Phase 2, 5 Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 7, Terminated 1, Withdrawn 1 |
| Phase 1 | 5 | Completed 4, Unknown 1 |
| Not applicable | 1 | Terminated 1 |
Follow DS Stage III Plasma Cell Myeloma: new trials by email Literature Review of DS Stage III Plasma Cell Myeloma trials Research Report on DS Stage III Plasma Cell Myeloma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Desipramine Hydrochloride and Filgrastim For Stem Cell Mobilization in Patients With Multiple Myeloma Undergoing Stem Cell Transplant Desipramine Hydrochloride, Filgrastim, Laboratory Biomarker Analysis - DS (Durie/Salmon) Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma | Not applicable | Terminated | Albert Einstein College of Medicine | 10 | 2013-09-01 | 2023-03-28 |
| Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple Myeloma Bortezomib, Total-Body Irradiation, Melphalan - DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma | Phase 1 | Completed | Mayo Clinic | 11 | 2013-08-01 | 2018-05-24 |
| Carfilzomib and Melphalan Before Stem Cell Transplant in Treating Patients With Multiple Myeloma Autologous Bone Marrow Transplantation, Autologous Hematopoietic Stem Cell Transplantation, Carfilzomib - DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma | Phase 1 / Phase 2 | Completed | Mayo Clinic | 50 | 2013-06-04 | 2020-09-01 |
| NK Cells in Cord Blood Transplantation Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Fludarabine Phosphate - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia | Phase 1 | Unknown | M.D. Anderson Cancer Center | 13 | 2013-05-03 | 2020-02-11 |
| S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma Bortezomib, Dexamethasone, Elotuzumab - DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma | Phase 1 / Phase 2 | Completed | SWOG Cancer Research Network | 142 | 2012-11-01 | 2026-04-28 |
| Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma Busulfan, Melphalan, Bortezomib - DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma | Phase 2 | Completed | Albert Einstein College of Medicine | 19 | 2012-02-01 | 2020-08-20 |
| Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple Myeloma Vismodegib, Pharmacological Study, Laboratory Biomarker Analysis - DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma | Phase 1 | Completed | National Cancer Institute (NCI) | 50 | 2010-12-01 | 2014-12-23 |
| RO4929097 After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma Autologous Hematopoietic Stem Cell Transplantation, Gamma-Secretase Inhibitor RO4929097, Hematopoietic Stem Cell Mobilization - DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2010-12-01 | 2017-09-28 | |
| Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Cyclophosphamide, Filgrastim, Fludarabine Phosphate - Acute Biphenotypic Leukemia, Acute Erythroid Leukemia in Remission | Phase 2 | Terminated | Fred Hutchinson Cancer Center | 46 | 2010-05-19 | 2023-01-23 |
| Bortezomib and Vorinostat in Treating Patients With Multiple Myeloma Who Have Undergone Autologous Stem Cell Transplant Bortezomib, Vorinostat - DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma | Phase 2 | Completed | Fred Hutchinson Cancer Center | 31 | 2009-02-01 | 2017-05-09 |
| Lenalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone Stem Cell Transplant for Multiple Myeloma Clarithromycin, Dexamethasone, Lenalidomide - DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma | Phase 2 | Completed | Fred Hutchinson Cancer Center | 32 | 2007-01-10 | 2019-11-13 |
| Bortezomib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Previously Untreated Symptomatic Multiple Myeloma Bortezomib, Laboratory Biomarker Analysis, Pegylated Liposomal Doxorubicin Hydrochloride - DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma | Phase 2 | Completed | National Cancer Institute (NCI) | 55 | 2004-06-15 | 2019-09-23 |
| FR901228 in Treating Patients With Relapsed or Refractory Multiple Myeloma Romidepsin, Laboratory Biomarker Analysis - DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma | Phase 2 | Completed | National Cancer Institute (NCI) | 50 | 2003-06-01 | 2015-03-17 |
Multiple Myeloma (9) · Hodgkin Disease (2) · Leukemia, Biphenotypic, Acute (2) · Myelodysplastic Syndromes (2) · Burkitt Lymphoma (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myeloid, Accelerated Phase (1) · Leukemia, Myeloid, Acute (1) · Leukemia, Myeloid, Chronic-Phase (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Follicular (1) · Lymphoma, Large-Cell, Anaplastic (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, Non-Hodgkin (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Hematologic Diseases (10) · Hemic and Lymphatic Diseases (10) · Immune System Diseases (10) · Immunoproliferative Disorders (10) · Lymphoproliferative Disorders (10) · Neoplasms (10) · Neoplasms by Histologic Type (10) · Blood Protein Disorders (9) · Cardiovascular Diseases (9) · Hemorrhagic Disorders (9) · Hemostatic Disorders (9) · Neoplasms, Plasma Cell (9) · Paraproteinemias (9) · Vascular Diseases (9) · Bone Marrow Diseases (2)
Bortezomib (5) · Melphalan (5) · Lenalidomide (3) · Peripheral Blood Stem Cell Transplantation (3) · Whole-Body Irradiation (3) · Calcium Dobesilate (2) · Cyclophosphamide (2) · Dexamethasone (2) · Filgrastim (2) · Granulocyte Colony-Stimulating Factor (2) · Mycophenolic Acid (2) · Tacrolimus (2) · auricularum (2) · dexamethasone 21-phosphate (2) · dexamethasone acetate (2)
National Cancer Institute (NCI) (4) · Fred Hutchinson Cancer Center (3) · Albert Einstein College of Medicine (2) · Mayo Clinic (2) · M.D. Anderson Cancer Center (1) · SWOG Cancer Research Network (1)
United States (13)
Leona Holmberg (2) · Carol Huff (1) · Chitra Hosing (1) · Ira Braunschweig (1) · Mecide Gharibo (1) · Murali Janakiram (1) · Rachel B. Salit (1) · Robert Z Orlowski (1) · Ruben Niesvizky-Iszaevich (1) · Saad Usmani (1) · Shaji Kumar (1) · Suzanne Hayman (1)
P30CA013330 (3), P30CA015083 (2), P30CA015704 (2), N01CM62204 (1), P30CA006973 (1), P30CA016672 (1), P30CA072720 (1), U01CA070095 (1), U01CA132194 (1), U10CA031946 (1), U10CA032102 (1), U10CA180821 (1), U10CA180888 (1), UM1CA186691 (1)